| BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement. SmallCapVoice.com, Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence. |
|
Check out SmallCapVoice on Facebook, Twitter and YouTube!
Follow or Like Us today! |
 |
Oncolix, Inc. (ONCX) Continues to Impress by Reaching Important Milestones
Oncolix Inc.
14405 Walters Road
Suite 780
Houston, Texas 77014
oncolixbio.com
Profile:
Oncolix is a clinical-stage biotechnology company developing Prolanta™ for the treatment of ovarian, uterine, breast and other cancers. The Company has a US FDA-cleared IND to commence human testing of Prolanta™ in its first indication, the treatment of ovarian cancer. This Phase 1 clinical trial is currently in progress. Prolanta™ is a prolactin receptor antagonist (or blocker) that has demonstrated efficacy in xenograft models through a unique mechanism of action, autophagy. In addition to ovarian cancer, there is strong preclinical evidence Prolanta™ may be effective in breast, prostate and other cancers. In the current Phase 1 dose-escalation safety trial for the treatment of ovarian cancer, to date there have been no observed serious adverse events and no dose-limiting toxicities. The FDA has approved the designation of Prolanta™ as an Orphan Drug for the treatment of ovarian cancer, which may result in reduced filing fees (currently 2 million dollars), federal tax credits and marketing exclusivity. Ovarian cancer still remains the leading cause of death among women with gynecological cancers and fourth most common cause of cancer-related deaths in women in the U.S. There are currently no effective treatment options. Early results from the first clinical trial for Prolanta™ are promising.
Recent Highlights:
- Initiated patient recruitment of the second dosing group of our first Prolanta™ clinical trial. The is ONCX’s primary objective and core value driver, which is to evaluate Prolanta™ in ovarian cancer patients with the ultimate goal of demonstrating its efficacy and safety and providing it as a breakthrough treatment option to patients.
- Completed the process and gained approval by the OTC Markets to be listed and traded on the OTC-QB effective at the opening of trading on December 19, 2017. The next phase in the Company’s development will also be, to continue strengthening our public company infrastructure including the creation of a Scientific/Clinical Advisory board.
- Announced the appointment of John W. Holaday, Ph.D., an accomplished CEO of several biopharmaceutical companies, to the Company’s Board of Directors as an independent board member.
Summary:
A Fresh Start
The company recently changed its stock symbol, began trading, and announced its intent to hit NASDAQ with a splash. CEO Michael Redman has gone to great lengths to bring unity to the company, so everyone is on the same page as the company prepares for its next steps. By shifting focus to their most promising development, Prolanta™, they hope to achieve global success in cancer treatment. Prolanta™ works to counteract the adverse effects of prolactin, an overexpressed hormone in those with ovarian, breast, and cervical cancers. By reducing the amount of the hormone, the drug is intended to shrink tumors. Redman is adding new independent members to his team, as well as an advisory board comprised of experts to ensure that Prolanta™ aces all clinical trials with flying colors.
Evidence-Based Success
One of the biggest reasons why Prolanta™ is being singled out by Oncolix is because of its initial studies and its lack of adverse side effects. There’s been evidence that suggests Prolanta™ may be able to reduce the tumors of women with reproductive-related tumors - even those who have late-stage cancer. Typically those with advanced cancer will not respond to any treatments, but Prolanta™ has already shown promise when it comes to treating tumors of all sizes. For the millions of people suffering from these types of cancer, it offers not only cautious optimism but hope toward easier and more effective treatments.
Global Reach
Oncolix is confident that Prolanta™ can be used everywhere so that all people can get the relief they need. The company is planning to get license rights for Prolanta™ to be sold in the Asian markets by seeking out Japanese and Chinese investment partners. They will be targeting the European market as well for an even greater reach. Prolanta™ currently shows no adverse effects, which is an obvious advantage when it comes to cancer treatment options. The protein works by regulating the amount of prolactin in the patient, which is typically found in high quantities for women with reproductive-related cancers.
While it’s clear that Prolanta™ is the star of the show, Oncolix is also looking into acquiring a number of other drug candidates for the future. Their focus is still in the oncology specialty, though they may branch out based on promising evidence of other therapies and treatments. Based on the milestones already achieved, it seems clear that the company has a bright future. |
|
OTCQB: ONCX
Market Value
4,352,486 a/o Jan 23, 2018
Authorized Shares
950,000,000 a/o Jan 02, 2018
Outstanding Shares
103,877,936 a/o Jan 02, 2018
Float
33,311,633 a/o Apr 06, 2017
Shareholders of Record
101 a/o Apr 06, 2017
Short Interest
2,103 (-84.1%) Nov 30, 2017
Transfer Agent:
VStock Transfer LLC
RECENT NEWS:
Oncolix Initiates Patient Recruitment of Second Cohort of Prolanta™ Phase 1 Trial in Advanced Ovarian Cancer
Oncolix, Inc., Announces Approval for Listing on OTC-QB
KEY EXECUTIVES:
Michael T. Redman
CEO
J. Donals Payne
CFO |
|
  |
SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from SmallCapVoice.com. You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website or in our e-mail communications. |
About Penny Stocks
|
|
